NCT05751837 - Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

May 30, 2024

Study Completion Date

May 30, 2024

Conditions

Abdominal CancerMalignancy

Interventions

BIOLOGICAL

Lipopolysaccharide

One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute

Trial Locations (2)

Allegheny Health Network Allegheny General Hospital, Pittsburgh

Allegheny Health Network West Penn Hospital, Pittsburgh